Advertisement

Topics

Syneos Health Schedules Third Quarter 2018 Earnings Call for Tuesday, November 6, 2018

20:00 EDT 18 Oct 2018 | Globe Newswire

RALEIGH, N.C., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Syneos HealthTM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its third quarter 2018 financial results on Tuesday, November 6, 2018, prior to its earnings call at 8:00 a.m. ET. 

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 6789942.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on November 6. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 6789942.

About Syneos Health
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

Investor Relations Contact:   Press/Media Contact:
Ronnie Speight Danielle DeForge
Senior Vice President, Investor Relations   Executive Director, External Communications
+1 919 745 2745     +1 781 425 2624
investor.relations@syneoshealth.comdanielle.deforge@syneoshealth.com

                         
                                                  
        
                                            
               


Syneos Health_rgb_tm.png

NEXT ARTICLE

More From BioPortfolio on "Syneos Health Schedules Third Quarter 2018 Earnings Call for Tuesday, November 6, 2018"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...